Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners
The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs) Its proprietary ADC technology opens the …